



**UNICHEM
LABORATORIES LTD.**

October 30, 2018

Department of Corporate Services
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

Mr. Hari K
Asst. Vice President - Operations
National Stock Exchange of India Ltd
Exchange Plaza, Bandra - Kurla Complex
Bandra (East), Mumbai - 400 051

Dear Sir,

Ref: BSE Scrip Code -506690: NSE Symbol - UNICHEMLAB

Sub: Outcome of Board Meeting held on Tuesday, October 30, 2018:

We would like to inform you that Board of Directors at its Meeting held today, i.e. Tuesday, October 30, 2018 approved the Unaudited Financial Results for the quarter and half year ended September 30, 2018.

Enclosed please find herewith the Unaudited Financial Results for the quarter and half year ended September 30, 2018 and the Limited Review report given by the statutory auditors.

The Board also:

- a. Approved allotment of 40,175 equity shares having a face value of Rs. 2/- each, pursuant to exercise of options under the Employees Stock Option Scheme, 2008.
- b. Designated Mr. Sandip Ghume GM- Accounts & Finance as Deputy CFO and Key Managerial Personnel of the Company with effect from October 30, 2018.

Mr. Ghume aged 37 years is a qualified Chartered Accountant with over 14 years of industry experience in the field of finance, accounts and tax. Before joining Unichem he has served reputed organizations namely Ambuja Cements, Mahindra & Mahindra and Hindalco Industries. He is not related to any Director of the Company.

The Board meeting commenced at 12 Noon and concluded at 2:00 pm

Kindly take the same on your records.

Thanking you,
FOR UNICHEM LABORATORIES LIMITED


N. N. Thakore

Neema Thakore
Head- Legal & Company Secretary
Encl: a/a



UNICHEM LABORATORIES LTD.

Statement of Standalone Unaudited Results for the Quarter & Half Year ended 30th September, 2018.							₹ Lakhs
Particulars	Quarter ended 30th Sep'18 (Unaudited)	Quarter ended 30th Jun'18 (Unaudited)	Quarter ended 30th Sep'17 (Unaudited)	Half year ended 30th Sep, 2018 (Unaudited)	Half year ended 30th Sep, 2017 (Unaudited)	For the year ended 31st Mar'18 (Audited)	
CONTINUING OPERATIONS							
I Revenue from operations (inclusive of excise duty - Refer note 8)	24,591.70	20,142.79	16,271.05	44,734.49	30,440.93	66,973.05	
II Other income	3,258.33	1,931.63	541.13	5,189.96	1,184.88	6,288.60	
III Total income (I+II)	27,850.03	22,074.42	16,812.18	49,924.45	31,625.81	73,261.65	
EXPENSES							
IV Cost of materials consumed	10,472.11	11,671.89	7,776.40	22,144.00	16,579.63	34,579.90	
Purchase of stock-in-trade	8.24	1.91	9.96	10.15	13.65	18.31	
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(451.00)	(1,490.19)	638.78	(1,941.19)	(824.47)	470.21	
Excise duty on sale of goods	-	-	-	-	39.34	39.34	
Employee benefits expense (Refer note 11)	4,132.34	4,212.65	3,670.95	8,344.99	7,231.15	14,653.83	
Finance costs	6.66	1.18	105.93	7.84	171.95	316.69	
Depreciation and amortization expense	1,481.32	1,234.94	1,081.08	2,716.26	2,076.04	4,504.12	
Other expenses (refer note 5)	10,248.42	9,611.86	8,441.67	19,860.29	13,028.63	30,834.49	
Total expenses (IV)	26,898.09	25,244.24	19,724.77	51,142.33	38,315.92	85,416.69	
V Profit/(loss) before exceptional items and tax (III-IV)	1,951.94	(3,169.82)	(2,912.59)	(1,217.88)	(6,690.11)	(12,155.04)	
VI Exceptional items	-	-	-	-	-	-	
VII Profit/(loss) before tax (V-VI)	1,951.94	(3,169.82)	(2,912.59)	(1,217.88)	(6,690.11)	(12,155.04)	
VIII Tax expense							
(1) Current tax (set off against tax on discontinued operations)	-	-	(590.94)	-	(590.94)	-	
(2) Deferred tax (Refer note 10)	183.81	(1,104.56)	986.41	(920.75)	1,761.39	1,257.90	
(3) Short / (excess) provision for tax (earlier years) (Refer note 7)	-	-	-	-	(1,235.87)	(1,271.99)	
IX Profit/(loss) for the period from continuing Operations (VII-VIII)	1,768.13	(2,065.26)	(3,308.06)	(297.13)	(6,624.69)	(12,140.95)	
DISCONTINUED OPERATIONS							
X Discontinued Operations (refer note 3)							
A. Profit/(loss) before tax from discontinued operations (Refer note 12)	(359.35)	-	9,600.92	(359.35)	13,073.21	15,358.12	
B. Gain on sale of identified business (net)	-	-	-	-	-	3,21,731.05	
Profit/(Loss) for the period from discontinued operations (A+B)	(359.35)	-	9,600.92	(359.35)	13,073.21	3,37,089.17	
Tax on discontinued operations (Refer note 9)	(112.00)	-	1,710.53	(112.00)	1,716.55	69,288.37	
X Profit/(loss) from discontinued operations (after tax)	(247.35)	-	7,890.39	(247.35)	11,356.66	2,67,800.80	
XI Profit/(loss) for the period (IX+X)	1,520.78	(2,065.26)	4,582.33	(544.48)	4,731.97	2,55,659.85	
Other Comprehensive Income/(Loss)							
XII Other Comprehensive Income/(Loss)							
A. (i) Items that will not be reclassified subsequently to profit or loss	138.02	(42.66)	-	95.36	-	(180.08)	
(ii) Income tax expense / (credit) relating to items that will not be reclassified to profit or loss	(44.19)	14.44	-	(29.75)	-	-	
B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	
Total of Other Comprehensive Income / (Loss)	93.83	(28.22)	-	65.61	-	(180.08)	
XIII Total Comprehensive Income for the period (XI+XII)	1,614.61	(2,093.48)	4,582.33	(478.87)	4,731.97	2,55,479.77	
XIV Paid-up equity share capital (Face value of ₹ 2/- per share)	1,406.86	1,406.74	1,818.38	1,406.86	1,818.38	1,406.74	
XV Other Equity (Reserves excluding revaluation reserve)						2,74,759.86	
Earnings per equity share (for continuing operation) in ₹:							
(1) Basic	2.51	(2.94)	(3.64)	(0.42)	(7.75)	(13.39)	
(2) Diluted	2.51	(2.94)	(3.64)	(0.42)	(7.73)	(13.38)	
Earnings per equity share (for discontinued operation) in ₹:							
(1) Basic	(0.35)	-	8.68	(0.35)	15.72	295.27	
(2) Diluted	(0.35)	-	8.67	(0.35)	15.69	295.08	
Earnings per equity share (for discontinued & continuing operation) in ₹:							
(1) Basic	2.16	(2.94)	5.04	(0.77)	7.97	281.88	
(2) Diluted	2.16	(2.94)	5.03	(0.77)	7.96	281.70	

SIGNED FOR IDENTIFICATION BY

 H. P. Wode
 N. A. SHAH ASSOCIATES LLP
 MUMBAI

Page 1 of 3






UNICHEM LABORATORIES LTD.

Notes :

- The unaudited standalone financial results for the quarter and half year ended 30th September, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 30th October, 2018. The statutory auditors have carried out a limited review of the standalone financial results for the quarter and half year ended 30th September, 2018.
- The above standalone financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 including Ind AS 115-Revenue from Contracts with Customers effective from 01-April-2018.
- During the year ended 31st March 2018, based on the approval obtained from the Shareholders, the Company had transferred its business of manufacture, sale, marketing and distribution of domestic formulations in India and Nepal ("Identified Business") by way of slump sale on going concern basis to Torrent Pharmaceuticals Limited ("Torrent"). Identified business includes portfolio of several brands in India and Nepal, manufacturing facility at Sikkim and employees performing work in relation to said business. Gain on sale of Identified Business (net) amounting to ₹ 321,731.05 lakhs had been recognised and disclosed under discontinued operations in the above results [Refer Serial no. X B above]. Pursuant to above transfer of Identified Business, reported figures for quarter ended 30th September 2017 and for half year ended 30th September 2017 are regrouped into continuing & discontinued operations.
- Operating Segment : The Company has a single reportable segment i.e. 'Pharmaceuticals'.
- Other expenses (continuing operations) include provision for impairment of long-term investments in Unichem Farmaceutica Do Brazil Ltda of ₹ Nil for the quarter ended 30th September 2018 (₹ 302.83 lakhs for the quarter ended 30th June, 2018, ₹ 64.40 lakhs for the quarter ended 30th September, 2017, ₹ 302.83 lakhs for the half year ended 30th September, 2018, ₹ 193.33 lakhs for the half year ended 30th September, 2017 and ₹ 511.71 lakhs for the year ended 31st March, 2018).
- During the quarter ended 30th September 2018, the Company has invested ₹ 3,187.80 lakhs in equity shares of its subsidiary "Niche Generics Limited (UK)" and ₹ 120.50 lakhs in equity shares of its subsidiary "Unichem Laboratories Limited (Ireland)". The above amount do not include value of guarantee commission and ESOP accounted in investments in accordance with Ind AS requirements.
- Short / excess provision for income tax (net) of earlier years is on account of reworking the provision for tax in respect of earlier years on the basis of acceptance of the Company's view in computation of tax liability under u/s 115JB (MAT) of the Income tax Act, 1961 as per assessment order passed by the tax authority.
- Revenue for periods reported upto 30th June, 2017 are inclusive of excise duty. As per Ind AS, the revenue is reported net of GST after 30th June, 2017. Accordingly, the revenue for the half year ended 30th September 2018 are not strictly comparable with the half year ended 30th September 2017 and year ended 31st March 2018.
- Tax on discontinued operations for the year ended 31st March, 2018 is net of MAT credit for earlier years recognised to the extent of utilisation.
- During the quarter ended 30th June 2018 and for the half year ended 30th September 2018, deferred tax assets is recognised on tax loss & unabsorbed depreciation which will be offset against deferred tax liability.
- For the quarter and half year ended 30th September 2018, managerial remuneration includes provision of ₹ 103.48 lakhs which is in excess of the limits specified under the Schedule V of the Companies Act 2013 and is subject to the Members approval.
- Loss in discontinued business for the quarter and half year ended 30th September 2018 mainly includes additional provision made towards doubtful recovery of amount receivable from the government authorities of ₹ 328.90 lakhs.
- Statement of Standalone Assets and Liabilities:

Particulars	₹ Lakhs	
	As at 30th Sep, 2018	As at 31st Mar, 2018
	Unaudited	Audited
Non-current assets		
(a) Property, plant and equipment	67,298.55	55,111.92
(b) Capital work-in-progress	13,144.59	23,553.08
(c) Investment property	369.05	372.22
(d) Financial assets		
(i) Investments	11,770.48	8,324.83
(ii) Loans	5.72	6.94
(iii) Other financial assets	1,482.82	940.58
(e) Other non-current assets	1,980.05	1,246.34
	96,051.26	89,558.91

SIGNED FOR IDENTIFICATION BY

 N. A. SHAH ASSOCIATES LLP
 MUMBAI





UNICHEM LABORATORIES LTD.

Particulars	₹ Lakhs	
	As at 30th Sep,2018	As at 31st Mar,2018
	Unaudited	Audited
Current assets		
(a) Inventories	23,726.11	20,775.60
(b) Financial Assets		
(i) Investments	47,747.21	89,555.14
(ii) Trade receivables	30,871.37	22,704.98
(iii) Cash and bank balances		
Cash & cash equivalents	81,006.71	66,064.03
Other bank balances	208.52	1,296.49
(iv) Loans	5.63	5.34
(v) Other financial assets	2,424.61	2,925.00
(c) Other current assets	24,566.90	17,409.21
	2,10,657.06	2,20,735.79
TOTAL ASSETS	3,06,608.32	3,10,291.70
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,406.86	1,406.74
(b) Other equity	2,70,125.88	2,74,759.86
	2,71,532.74	2,76,166.60
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	29.21	32.68
(b) Provisions	1,127.09	1,075.90
(c) Deferred tax liabilities (net)	2,426.01	3,429.01
	3,582.31	4,537.59
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	23,236.59	21,150.94
(ii) Other financial liabilities	2,721.42	4,164.87
(b) Other current liabilities	4,804.30	1,875.13
(c) Provisions	730.96	1,935.27
(d) Current tax liabilities (net)	-	461.25
	31,493.27	29,587.51
TOTAL EQUITY AND LIABILITIES	3,06,608.32	3,10,291.70

By Order of the Board
For Unichem Laboratories Limited

Dr. Prakash A. Mody
Chairman & Managing Director
DIN : 00001285



Place: Mumbai
Date: 30th October, 2018

SIGNED FOR IDENTIFICATION BY
A. V. Mody
N.A. SHAH ASSOCIATES LLP

Limited Review Report on quarterly and half yearly standalone financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors
M/s. Unichem Laboratories Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Unichem Laboratories Limited ("the Company") for the quarter and half year ended 30th September, 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular no.CIR/CFD/FAC/62/2016 dated 5th July 2016 which has been initialed by us for identification purpose.

2. Management's responsibility for the Statement

The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors.

3. Auditor's responsibility

Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

4. Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards i.e. 'Ind AS' prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.



N. A. SHAH ASSOCIATES LLP
Chartered Accountants

Limited Review Report on quarterly and half yearly standalone financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (continued...)

5. Emphasis of matter

We draw attention to Note 11 to the Statement regarding provision of Rs.103.48 lakhs made for managerial remuneration in excess of the limits specified under the Schedule V of the Companies Act, 2013, which is subject to Members approval.

Our conclusion is not modified in respect of this matter.

For N. A. Shah Associates LLP

Chartered Accountants

Firm's registration number: 116560W / W100149

M. V. Mody



Milan Mody

Partner

Membership number: 103286

Place: Mumbai

Date: **30 OCT 2018**